Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but the gains didn't last long. Since reaching a peak last May, Moderna ...

sentiment for Moderna plunged to ‘extremely bearish’ levels, hitting levels last seen in February 2024. Meanwhile, soaring message volume drove the ticker into the top three trending symbols ...